STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules

Rhea-AI Summary

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.

The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.

Positive

• Secured immediate funding of $2.42 million for working capital
• Successfully arranged institutional investment at market price
• Offering conducted through existing shelf registration, streamlining the process

Negative

• Potential dilution for existing shareholders
• Relatively small offering size may indicate limited investor interest

Insights

Financial Analyst

STRATA's $2.42M offering likely indicates cash needs while attempting to minimize dilution through at-market pricing.

STRATA Skin Sciences is raising $2.42 million in fresh capital through a registered direct offering of 1,097,547 shares at $2.204 per share. This relatively small capital raise, priced at-market under Nasdaq rules, suggests the company needed to bolster its working capital without offering the typical discount seen in many secondary offerings.

The at-market pricing is somewhat unusual and indicates the company's attempt to minimize dilution while still securing necessary funds. For context, registered direct offerings allow companies to sell securities directly to selected institutional investors rather than through a broader public offering, typically resulting in lower fees and faster execution.

With Ladenburg Thalmann serving as the placement agent, this offering represents a targeted approach to fundraising. The stated use of proceeds for "working capital and general corporate purposes" is notably vague, potentially signaling immediate operational cash needs rather than specific growth initiatives or debt reduction.

This capital raise, while relatively modest, will increase the company's outstanding share count and dilute existing shareholders. Investors should consider whether this $2.42 million provides sufficient runway for STRATA's business needs or whether additional financing might be required in the near future.

HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204, in a registered direct offering, priced at-market under Nasdaq rules.

Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering.

The closing of the registered direct offering is expected to occur on or about September 4, 2025, subject to the satisfaction of customary closing conditions.

The gross proceeds to The Company from the registered direct offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $2.42 million. The Company intends to use the net proceeds from the offerings for working capital and for general corporate purposes.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283418), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 18, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
  
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. For more information, please visit www.strataskinsciences.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

FAQ

What is the size and price of STRATA Skin Sciences (SSKN) September 2025 offering?

STRATA is offering 1,097,547 shares at $2.204 per share, totaling approximately $2.42 million in gross proceeds.

How will STRATA Skin Sciences use the proceeds from the $2.42M offering?

STRATA plans to use the net proceeds for working capital and general corporate purposes.

Who is the placement agent for SSKN's September 2025 stock offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

When will STRATA Skin Sciences' registered direct offering close?

The offering is expected to close on or about September 4, 2025, subject to customary closing conditions.

What type of investors are participating in SSKN's $2.42M offering?

The offering is being conducted with institutional investors through definitive securities purchase agreements.